Avoid the seven most common tissue cross-reactivity planning mistakes, from late starts to unreliable methods, that can put your IND, CTA or first-in-human timeline at risk.
Avoid the seven most common tissue cross-reactivity planning mistakes, from late starts to unreliable methods, that can put your IND, CTA or first-in-human timeline at risk.
The road to bringing a medical device to market is fraught with potential regulatory pitfalls and decisions that can delay—or even derail—your efforts.
As part of the World Health Organization (WHO), the International Agency for Research on Cancer (IARC) works to identify potential carcinogenic hazards to humans.
Immunohistochemistry (IHC) and immunofluorescence (IF) are molecular assays that involve the use of antibodies to detect specific proteins within tissues on microscope slides
513.204.4400
